Patient with osseous metastatic prostatic cancer can clinically be detected by bone scanning, which usually is sensitive and qualitative but is not specific and quantitative. For quantitative evaluation of skeletal lesions, we measured bone
mineral
density (BMD) in whole body, total spine and lumbar spine. All patients also were assessed with bone radiography, radionuclide hone scan, prostate specific antigen (PSA), and prostatic acid phosphatase (PAP).
We compared mainly bone scan and BMD in monitoring tumor response between before hormonal treatment and 6 month after hormonal treatment. Fifteen patients with stage D2 prostate cancer and 25 controls were entered in this study. Of 8 patines
whose
scan
showed response in 12 patines with metastatic lumbar spine lesion, they had either 7 responsed or 1 unchanged BMD level in the lumbar spine. Of 9 patients whose scan showed response in 15 patines with metastatic total spine lesion, they had
either
6
responsed or 3 unchanged BMD level in the total spine. The alterations of BMD levels in total spine and lumbar spine closely correlated with the therapeutic responses assessed by the National Prostatic Cancer Projet Criteria of bone scintigraphy
in
patients with prostatic cancer (spine: r=0.047, p<0.05; lumbar: r=0.1, p<0.05). In contrast. BMD changes in whole body (response rate: 20.0%, P<0.05) was less than that in total spme (response rate: 53.3%, P<0.01) and lumbar spine (response rate:
58.3%,
P<0.01).
In conclusion, when compare BND to the hot spot region in bone scan, BMD may be helpful to the urologist for the accuracy of staging and evaluation of the treatment response to androgen deprivation therapy in metastatic prostate cnacer.
|